Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 20,915 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

CBD Cannabis Extract: Pharmacokinetic Studies

NCT04280289
View directory record Official record
Conditions
Epilepsy
Interventions
cannabidiol extract
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 30, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

NCT05775289
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Detroit, Michigan • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study

NCT02622568
View directory record Official record
Conditions
Verruca, Warts
Interventions
Veregen only, Cryotherapy and Veregen
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 16 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 30, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 30, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 and the Healthy Minds Program for Educators

NCT04426318
View directory record Official record
Conditions
Anxiety, Depression, Psychological Stress, Psychological Distress, Well-being
Interventions
Healthy Minds Program Foundations Training
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis

NCT06656325
View directory record Official record
Conditions
Periodontal Diseases, Periodontitis, Gum Disease
Interventions
Erchonia® FX405, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Thousand Oaks, California • Acton, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

NCT00186576
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myeloproliferative Disorders, Blood and Marrow Transplant (BMT), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD)
Interventions
nonmyeloablative allogeneic hematopoietic cell transplant
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Oct 30, 2026, 10:27 PM EDT
Completed No phase listed Observational

Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC

NCT02677376
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
18F-Sodium Fluoride (NaF)
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 30, 2026, 10:27 PM EDT
Not yet recruiting Not applicable Interventional

Chronic Pain Optimization and Management for Relief and Functionality With TEA in Cirrhosis

NCT07820917
View directory record Official record
Conditions
Cirrhosis
Interventions
Transcutaneous Electrical Acustimulation (TEA), Sham Transcutaneous Electrical Acustimulation (TEA)
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

NCT05788289
View directory record Official record
Conditions
Mantle Cell Lymphoma, MCL
Interventions
Tafasitamab, Lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 30, 2026, 10:27 PM EDT
Completed Not applicable Interventional

An Online Mindfulness Intervention for People With ALS and Their Caregivers

NCT03095989
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Mindfulness
Behavioral
Lead sponsor
Harvard University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 30, 2026, 10:27 PM EDT
Terminated Not applicable Interventional Results available

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

NCT00685750
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Collection of tumor and blood samples
Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Park Ridge, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 30, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

NCT02631174
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Cardiopulmonary Bypass
Interventions
Antithrombin III
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 1 Year
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 30, 2026, 10:27 PM EDT
Completed No phase listed Observational

Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage

NCT01799018
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm, Hydrocephalus
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 30, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

NCT06618612
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care, PuraPly AM, PuraPly XT
Other · Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Clevland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 30, 2026, 10:27 PM EDT
Terminated Not applicable Interventional

Comparison of INFIX and Plating for Pelvic Ring Injuries With Symphysis Disruptions

NCT02399319
View directory record Official record
Conditions
Anterior Pelvic Ring Injury With Symphysis Disruption
Interventions
Internal Fixator, Symphyseal Plate
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 30, 2026, 10:27 PM EDT
Active, not recruiting Phase 2 Interventional

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

NCT04587128
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 10:27 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

NCT04190628
View directory record Official record
Conditions
Advanced Solid Tumor, BRAF V600 Mutation
Interventions
ABM-1310, Cobimetinib
Drug
Lead sponsor
ABM Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
San Francisco, California • Stanford, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 30, 2026, 10:27 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT02180867
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
365
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 10:27 PM EDT
Not yet recruiting Not applicable Interventional

MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma

NCT07783607
View directory record Official record
Conditions
Multiple Myeloma, Heart Disease Risk Factors
Interventions
Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway
Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 30, 2026, 10:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

NCT04544592
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma
Interventions
CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 30 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

NCT01035463
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Lenalidomide, Melphalan, Rituximab
Procedure · Drug · Biological
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Westwood, Kansas • Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 30, 2026, 10:27 PM EDT
Recruiting Phase 1 Interventional

Vascular Endothelial Dysfunction in Sleep Apnea

NCT05289063
View directory record Official record
Conditions
Obstructive Sleep Apnea of Adult
Interventions
Atorvastatin 10mg, Placebo, Continuous Positive Airway Pressure Therapy
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 30, 2026, 10:27 PM EDT